ATROVENT NASAL SPRAY 0.06% Rx
Generic Name and Formulations:
Ipratropium bromide 0.06% (42mcg/spray); aqueous soln.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT NASAL SPRAY 0.06%:
Rhinorrhea associated with the common cold.
Adults and Children:
<5yrs: not recommended. 5–11yrs: 2 sprays in each nostril 3 times daily. ≥12yrs: 2 sprays in each nostril 3–4 times daily.
Allergy to atropine or its derivatives.
Avoid eyes. Narrow-angle glaucoma. GI or GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Epistaxis, dry mouth or throat, nasal congestion or dryness.
Nasal spray—15mL (165 sprays)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy